IDEAYA Biosciences, Inc. (IDYA)
Stock Price:
$14.46 USD
0.73 (5.32%)
Updated Jul 6, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
391.38M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-44.45M |
| Shares Out |
27.07M |
| EPS (ttm) |
-2.57 |
| PE Ratio |
n/a |
| Forward PE |
5.83 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 6, 2020 |
| Last Price |
$14.46 |
| Previous Close |
$13.73 |
| Change ($) |
0.73 |
| Change (%) |
5.32% |
| Day's Open |
13.87 |
| Day's Range |
13.31 - 14.73 |
| Day's Volume |
466,489 |
| 52-Week Range |
2.95 - 19.97 |
More Stats
| Market Cap |
391.38M |
| Enterprise Value |
309.91M |
| Earnings Date (est) |
Aug 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
27.07M |
| Float |
11.74M |
| EPS (basic) |
-2.64 |
| EPS (diluted) |
-2.57 |
| FCF / Share |
-1.97 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
219,354 |
| Short Ratio |
4.26 |
| Short % of Float |
2.10% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
5.83 |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
4.32 |
| Revenue |
n/a |
| Operating Income |
-46.66M |
| Net Income |
-44.45M |
| Free Cash Flow |
-39.82M |
| Net Cash |
81.47M |
| Net Cash / Share |
3.01 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-29.99% |
| ROE |
-52.47% |
| ROIC |
-64.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
5 |
| Overweight |
1 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$20.43*
(41.29% upside)
Low
13.0
Current: 14.46
High
27.0
Target: 20.43
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -44.27 | -36.42 | -14.44 |
| Net Income | -41.98 | -34.35 | -11.86 |
| Shares Outstanding | 12.50 | 0.96 | 0.70 |
| Earnings Per Share | -3.36 | -35.92 | -17.06 |
| Operating Cash Flow | -39.31 | -27.62 | -12.22 |
| Capital Expenditures | -1.35 | -1.71 | -1.76 |
| Free Cash Flow | -40.67 | -29.33 | -13.98 |
| Cash & Equivalents | 99.06 | 90.07 | 13.23 |
| Total Debt | 6.77 | - | - |
| Net Cash / Debt | 92.29 | 90.07 | 13.23 |
| Assets | 113 | 96.54 | 17.48 |
| Liabilities | 12.60 | 7.10 | 7.13 |
| Book Value | 100 | -48.95 | -15.74 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
IDEAYA Biosciences, Inc. |
| Country |
United States |
| Employees |
43 |
| CEO |
Yujiro S. Hata |
Stock Information
| Ticker Symbol |
IDYA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: IDYA |
Description
IDEAYA Biosciences, Inc., an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase 1/2 clinical trial for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A for solid tumors with MTAP deletions; Pol-theta in tumors with homologous recombination deficiency, including BRCA mutations; PARG in tumors with BRCA2 mutations in base excision repair; and WRN in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase 1/2 study in metastatic uveal melanoma and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was founded in 2015 and is headquartered in South San Francisco, California.